PFE vs TTD: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and The Trade Desk, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
The Trade Desk, Inc. · Communication Services
$18.51
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
TTD has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
TTD |
| Current Price |
$25.22 |
$18.51 |
| Fair Value Estimate |
$25.92 |
$26.84 |
| Upside to Fair Value |
+2.8%
|
+45.0%
|
| Market Cap |
$143.7B |
$8.7B |
| Forward P/E |
19.2x
|
20.3x
|
| EV / EBITDA |
12.3x
|
10.5x
|
| Price / Sales |
2.3x
|
2.9x
|
| Price / FCF |
15.2x
|
10.4x
|
| Revenue Growth YoY |
+5.4%
|
+11.8%
|
| Gross Margin |
69.3%
|
77.8%
|
| Operating Margin |
23.4%
|
20.3%
|
| Return on Equity |
8.4%
|
16.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.6%
|
9.62%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
The Trade Desk operates a leading demand-side platform in the advertising technology sector, specializing in programmatic ad buying with a strong focus on connected TV, retail media, audio, and international markets. The company benefits from a durable competitive moat driven by founder-led management with over 15 years of continuity, a differentiated open-internet infrastructure, and a dominant …
Accumulation Zones
| Metric |
PFE |
TTD |
| Zone Low |
$19.44 |
$20.13 |
| Zone High |
$22.03 |
$22.81 |
| In Buy Zone? |
No
|
Yes
|